Latest Insider Transactions at Pacira Bio Sciences, Inc. (PCRX)
This section provides a real-time view of insider transactions for Pacira Bio Sciences, Inc. (PCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pacira BioSciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pacira BioSciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
500
-0.43%
|
$6,000
$12.86 P/Share
|
|
Aug 16
2024
|
Laura Brege Director |
BUY
Open market or private purchase
|
Direct |
1,000
+5.39%
|
$12,000
$12.81 P/Share
|
|
Aug 16
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
1,512
+12.97%
|
$19,656
$13.25 P/Share
|
|
Aug 14
2024
|
Michael J. Yang Director |
BUY
Open market or private purchase
|
Direct |
2,000
+21.67%
|
$24,000
$12.9 P/Share
|
|
Aug 12
2024
|
Frank D. Lee Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
8,264
+7.12%
|
$99,168
$12.1 P/Share
|
|
Aug 12
2024
|
Marcelo Bigal Director |
BUY
Open market or private purchase
|
Direct |
3,400
+28.26%
|
$40,800
$12.01 P/Share
|
|
Aug 12
2024
|
Mark Froimson Director |
BUY
Open market or private purchase
|
Direct |
1,400
+8.82%
|
$15,400
$11.58 P/Share
|
|
Aug 02
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
945
-0.99%
|
$18,900
$20.05 P/Share
|
|
Aug 01
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-0.32%
|
$6,100
$20.75 P/Share
|
|
Jul 02
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,836
-2.88%
|
$79,408
$28.25 P/Share
|
|
Jul 01
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-0.92%
|
$25,592
$28.46 P/Share
|
|
Jun 28
2024
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
437
+0.44%
|
$10,488
$24.32 P/Share
|
|
Jun 28
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160
+0.14%
|
$3,840
$24.32 P/Share
|
|
Jun 13
2024
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
7,452
-6.75%
|
$208,656
$28.38 P/Share
|
|
Jun 13
2024
|
Paul J Hastings Director |
SELL
Open market or private sale
|
Direct |
880
-6.47%
|
$24,640
$28.38 P/Share
|
|
Jun 13
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,000
-0.85%
|
$28,000
$28.38 P/Share
|
|
Jun 12
2024
|
Marcelo Bigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Christopher Christie Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+33.27%
|
-
|
|
Jun 12
2024
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+35.45%
|
-
|
|
Jun 12
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
3,970
-9.44%
|
$111,160
$28.72 P/Share
|
|
Jun 12
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
21,360
+33.69%
|
-
|
|
Jun 12
2024
|
Mark A. Kronenfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+17.36%
|
-
|
|
Jun 12
2024
|
Laura Brege Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+24.01%
|
-
|
|
Jun 12
2024
|
Kristen Marie Williams Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+32.98%
|
-
|
|
Jun 12
2024
|
Paul J Hastings Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+27.77%
|
-
|
|
Jun 12
2024
|
Alethia Young Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Mark Froimson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+28.57%
|
-
|
|
Jun 12
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,300
+31.69%
|
-
|
|
Jun 12
2024
|
Abraham Ceesay Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Michael J. Yang Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,230
+50.0%
|
-
|
|
Jun 12
2024
|
Charles A. Reinhart Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,220
+19.07%
|
-
|
|
Jun 11
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,012
-10.11%
|
$140,336
$28.57 P/Share
|
|
Jun 03
2024
|
Kristen Marie Williams Chief Administrative Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,011
-5.1%
|
$90,330
$30.89 P/Share
|
|
Jun 03
2024
|
Charles A. Reinhart Iii Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,979
-6.99%
|
$89,370
$30.89 P/Share
|
|
Jun 03
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
1,843
-8.18%
|
$55,290
$30.89 P/Share
|
|
Jun 03
2024
|
Jonathan Slonin Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,615
-3.15%
|
$48,450
$30.89 P/Share
|
|
Jun 03
2024
|
Daryl Gaugler Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,754
-4.21%
|
$82,620
$30.89 P/Share
|
|
Mar 08
2024
|
Gary W Pace Director |
SELL
Open market or private sale
|
Direct |
90,000
-80.27%
|
$2,700,000
$30.6 P/Share
|
|
Mar 07
2024
|
Gary W Pace Director |
SELL
Open market or private sale
|
Direct |
28,257
-20.13%
|
$847,710
$30.81 P/Share
|
|
Mar 06
2024
|
Gary W Pace Director |
SELL
Open market or private sale
|
Direct |
1,066
-0.75%
|
$30,914
$29.67 P/Share
|
|
Feb 05
2024
|
Kristen Marie Williams Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,700
+36.32%
|
-
|
|
Feb 05
2024
|
Daryl Gaugler Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,700
+33.97%
|
-
|
|
Jan 02
2024
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Payment of exercise price or tax liability
|
Direct |
159
-0.7%
|
$5,088
$32.0 P/Share
|
|
Jan 02
2024
|
Frank D. Lee Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,520
+50.0%
|
-
|
|
Jan 02
2024
|
Jonathan Slonin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+8.9%
|
-
|
|
Aug 02
2023
|
Roy Winston Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
509
-0.96%
|
$17,306
$34.88 P/Share
|
|
Jul 05
2023
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
643
-2.76%
|
$24,434
$38.91 P/Share
|
|
Jun 14
2023
|
Roy Winston Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,950
+17.31%
|
-
|
|
Jun 14
2023
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
6,366
-7.44%
|
$241,908
$38.33 P/Share
|
|
Jun 14
2023
|
Lauren Bullaro Riker Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+25.61%
|
-
|